Y. Bayon, A. Vertès, and V. Ronfard, Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products, Tissue Engineering Part B: Reviews, vol.21, issue.6, pp.560-71, 2015.
DOI : 10.1089/ten.teb.2015.0068

M. Drummond, D. Wilson, P. Kanavos, P. Ubel, and J. Rovira, Assessing the economic challenges posed by orphan drugs, International Journal of Technology Assessment in Health Care, vol.22, issue.01, p.36, 2007.
DOI : 10.1016/0168-8510(93)90042-N

L. Garrison, A. Towse, and A. Briggs, Performance-Based Risk-Sharing Arrangements???Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force, Value in Health, vol.16, issue.5, pp.703-719, 2013.
DOI : 10.1016/j.jval.2013.04.011

L. Coulton, L. Annemans, J. J. Brown, R. Keskinaslan, and A. , Risk-sharing Schemes Worldwide: A Landscape Analysis of Health Outcomes based Reimbursement Agreements (2010). https

A. Navarria, V. Drago, and L. Gozzo, Do the Current Performance-Based Schemes in Italy Really Work? ???Success Fee???: A Novel Measure for Cost-Containment of Drug Expenditure, Value in Health, vol.18, issue.1, pp.131-136, 2015.
DOI : 10.1016/j.jval.2014.09.007

L. Prior, Using Documents in Social Research, Sage, 2003.
DOI : 10.4135/9780857020222

A. Faulkner, Law???s performativities: Shaping the emergence of regenerative medicine through European Union legislation, Social Studies of Science, vol.42, issue.5, pp.753-774, 2012.
DOI : 10.1177/0162243908329188

K. Hofman, C. Kanyengo, B. Rapp, and S. Kotzin, Mapping the health research landscape in Sub-Saharan Africa: a study of trends in biomedical publications, Journal of the Medical Library Association : JMLA, vol.97, issue.1, pp.41-44, 2009.
DOI : 10.3163/1536-5050.97.1.007

J. Chilvers, Environmental Risk, Uncertainty, and Participation: Mapping an Emergent Epistemic Community, Environment and Planning A, vol.40, issue.12, pp.2990-3008, 2008.
DOI : 10.1007/978-94-011-0131-8_3

C. Helgesson and H. Kjellberg, Introduction: Values and Valuations in Market Practice, Journal of Cultural Economy, vol.15, issue.4, pp.361-369, 2013.
DOI : 10.1086/226828

A. Harzing, R. Wal, and . Van-der, Google Scholar as a new source for citation analysis, Ethics in Science and Environmental Politics, vol.8, issue.1, pp.61-73, 2008.
DOI : 10.3354/esep00076

D. Winter, J. Zadpoor, A. Dodou, and D. , The expansion of Google Scholar versus Web of Science: a longitudinal study, Scientometrics, vol.29, issue.3, pp.1547-1565, 2014.
DOI : 10.1126/science.1058040

S. Mikki, Google Scholar compared to Web of Science. A Literature Review, Nordic Journal of Information Literacy in Higher Education, vol.1, issue.1, pp.41-51, 2009.
DOI : 10.15845/noril.v1i1.10

A. Weale and K. Kieslich, Web of Science, or Google Scholar? A behind-the-scenes guide for life scientists. : So which is better: PubMed, Web of Science, or Google Scholar Challenges for the new Cancer Drugs Fund, Lancet Oncol, vol.17, issue.4, pp.416-424, 2016.

D. Sipp, Conditional Approval: Japan Lowers the Bar for Regenerative Medicine Products, Cell Stem Cell, vol.16, issue.4, pp.353-359, 2015.
DOI : 10.1016/j.stem.2015.03.013

A. , B. Bia, and A. , Adaptive Licensing, Documents/early_access_to_medicines_scheme .pdf 26 CASMIABPI-BIA-CASMI-Adaptive- Licensing-Meeting-Report.pdf 27 Life sciences UK. From vision to action: Delivery of the Strategy for UK Life Sciences, 2014.

J. Mestre-ferrandiz, A. Mordoh, and J. Sussex, The many faces of Innovation, A report for ABPI by the Office of Health Economics, 2012.

J. Mestre-ferrandiz and A. Towse, Office of Health Economics Maximising R&D Productivity: new initiatives and gaps in the analysis, ABPI, Adapting the innovation landscape, UK Biopharma R&D sourcebook 2015, pp.11-14, 2015.

N. Mount, S. Ward, P. Kefalas, and J. Hyllner, Cell-based therapy technology classifications and translational challenges, Philosophical Transactions of the Royal Society B: Biological Sciences, vol.32, issue.1680, p.20150017, 1680.
DOI : 10.1108/S0731-2199(2010)0000022004

URL : http://rstb.royalsocietypublishing.org/content/royptb/370/1680/20150017.full.pdf

J. Gardner, A. Faulkner, A. Mahalatchimy, and A. Webster, Are there specific translational challenges in regenerative medicine? Lessons from other fields, Regenerative Medicine, vol.2, issue.3, pp.885-895, 2015.
DOI : 10.1016/j.hlpt.2014.10.014

S. Gerke and S. Pattinson, EU Marketing Authorisation of Orphan Medicinal Products and Its Impact on Related Research, European Journal of Health Law, vol.24, issue.5, pp.1-24, 2017.
DOI : 10.1163/15718093-12341439

T. Bubela, C. Mccabe, P. Archibald, H. Atkins, S. Bradshaw et al., Bringing regenerative medicines to the clinic: the future for regulation and reimbursement, Regenerative Medicine, vol.20, issue.10, pp.897-911, 2015.
DOI : 10.1016/j.jval.2014.08.1176

B. Sullivan, D. Orenstein, and C. Milla, Pricing for Orphan Drugs, JAMA, vol.310, issue.13, pp.1343-1344, 2013.
DOI : 10.1001/jama.2013.278129

J. Adamski, B. Godman, G. Ofierska-sujkowska, B. Osinska, H. Herholz et al., Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers, BMC Health Services Research, vol.326, issue.1, p.153, 2010.
DOI : 10.1136/bmj.326.7385.388

C. Campillo-artero, J. Del-llano, and J. Poveda, Risk sharing agreements: with orphan drugs?]. Farm Hosp, pp.455-63, 2012.